Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01110746
Other study ID # VIAject -032J
Secondary ID
Status Completed
Phase Phase 3
First received April 13, 2010
Last updated July 30, 2015
Start date February 2010
Est. completion date June 2010

Study information

Verified date July 2015
Source Biodel
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 2010
Est. primary completion date June 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Males or females diagnosed with type 1 diabetes mellitus for at least 6 months

2. Current usage of subcutaneous insulin pump treatment with one of the following pumps:

- Medtronic Paradigm®

- Animas®

- OmniPod®

- ACCU-CHEK Spirit®

3. Age 18-75 years

4. HbA1c of 6.0 - 9.0% at screening visit.

5. Willingness to attend 9 clinic visits.

Exclusion Criteria:

1. Pregnancy or Lactation

2. Renal insufficiency (serum creatinine of 2.0 mg/dL or greater).

3. Anemia

4. Congestive heart failure.

5. Visual impairment preventing reading of glucose meter values or the ability to use an insulin pump or continuous glucose monitoring device.

6. Active coronary artery disease or heart procedure within the past 4 months.

7. Active foot ulceration.

8. Severe peripheral arterial disease.

9. Stroke within the past 6 months.

10. Active alcohol abuse, substance abuse, or severe mental illness.

11. Active cancer, except basal cell or squamous cell skin cancers.

12. Major surgical operation within 30 days prior to screening.

13. Seizure disorder (epilepsy).

14. Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen.

15. Currently use of corticosteroids.

16. History of major non-compliance.

17. Use of an investigational drug within 30 days prior to screening.

18. Bleeding disorder, treatment with warfarin, or low platelet count.

19. Any insulin allergy

20. Current complaints of major infusion site problems with commercially- available insulin preparations, such as frequent occurrence of infections, marked swelling or marked erythema.

21. History of gastroparesis.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Viaject 7
100IU/mL administered subcutaneously
LISPRO
100IU/mL administered subcutaneously

Locations

Country Name City State
United States Oregon Health and Science University/Legacy Health System Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Biodel

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3 hour incremental area under the glucose curve after a standardized high glycemic index meal. 3 hours No
Secondary Draize scores at insulin infusion site at 24 hour and 72 hour follow-up visits, frequency of discomfort with insulin infusion, and severity of discomfort with insulin infusion (ratings of mild, moderate, or severe). 72 hours No
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02558491 - Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM N/A
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A